MA27389A1 - Derives de benzimidazole nouveaux utiles comme agents antiproliferatifs. - Google Patents
Derives de benzimidazole nouveaux utiles comme agents antiproliferatifs.Info
- Publication number
- MA27389A1 MA27389A1 MA28124A MA28124A MA27389A1 MA 27389 A1 MA27389 A1 MA 27389A1 MA 28124 A MA28124 A MA 28124A MA 28124 A MA28124 A MA 28124A MA 27389 A1 MA27389 A1 MA 27389A1
- Authority
- MA
- Morocco
- Prior art keywords
- compounds
- formula
- benzimidazole derivatives
- derivatives useful
- antiproliferative agents
- Prior art date
Links
- 230000001028 anti-proliverative effect Effects 0.000 title abstract 2
- 229940058303 antinematodal benzimidazole derivative Drugs 0.000 title abstract 2
- 150000001556 benzimidazoles Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 125000003785 benzimidazolyl group Chemical class N1=C(NC2=C1C=CC=C2)* 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000010261 cell growth Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000002243 precursor Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
DEPOSANT Société dite : PFIZER PRODUCTS INC. Mandataire SANTABELLI REVENDICATION DE PRIORITES US 28 Août 2002 60/406,524 US 8 Octobre 2002 60/417,047 Dérivés de benzimidazole nouveaux utiles comme agents antiproliferatifs La présente invention concerne des composés de formule (1] et leurs sels, précurseurs médicamenteux et produits de solvatation pharmaceutiquement acceptables, formule dans laquelle R1, R2, R3 et R4 répondent aux définitions figurant dans le présent mémoire. La présente invention concerne également des méthodes pour le traitement d'une croissance cellulaire anormale, telle qu'un cancer, chez des mammifères en administrant les composés de formule (1), et des compositions pharmaceutiques pour le traitement de telles affections, qui contiennent les composés de formule (1). La présente invention concerne également des procédés pour la préparation des composés de formule (1).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40652402P | 2002-08-28 | 2002-08-28 | |
| US41704702P | 2002-10-08 | 2002-10-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA27389A1 true MA27389A1 (fr) | 2005-06-01 |
Family
ID=31981411
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA28124A MA27389A1 (fr) | 2002-08-28 | 2005-02-28 | Derives de benzimidazole nouveaux utiles comme agents antiproliferatifs. |
Country Status (40)
| Country | Link |
|---|---|
| US (1) | US7071337B2 (fr) |
| EP (1) | EP1594858B1 (fr) |
| JP (1) | JP4551771B2 (fr) |
| KR (2) | KR100816166B1 (fr) |
| CN (1) | CN1319966C (fr) |
| AP (1) | AP2005003237A0 (fr) |
| AR (1) | AR041055A1 (fr) |
| AT (1) | ATE445610T1 (fr) |
| AU (1) | AU2003250499B2 (fr) |
| BR (1) | BRPI0313942C1 (fr) |
| CA (1) | CA2495577C (fr) |
| CR (1) | CR7698A (fr) |
| CU (1) | CU23413B7 (fr) |
| CY (1) | CY1110580T1 (fr) |
| DE (1) | DE60329715D1 (fr) |
| DK (1) | DK1594858T3 (fr) |
| DO (1) | DOP2003000694A (fr) |
| EA (1) | EA008448B1 (fr) |
| EC (1) | ECSP055633A (fr) |
| ES (1) | ES2333219T3 (fr) |
| GE (1) | GEP20064005B (fr) |
| HN (1) | HN2003000257A (fr) |
| HR (1) | HRP20050191B1 (fr) |
| IL (1) | IL166832A (fr) |
| IS (1) | IS2738B (fr) |
| MA (1) | MA27389A1 (fr) |
| MX (1) | MXPA05001256A (fr) |
| MY (1) | MY139357A (fr) |
| NO (1) | NO20051303L (fr) |
| NZ (1) | NZ538427A (fr) |
| OA (1) | OA12916A (fr) |
| PA (1) | PA8580301A1 (fr) |
| PE (1) | PE20050131A1 (fr) |
| PL (1) | PL377678A1 (fr) |
| PT (1) | PT1594858E (fr) |
| RS (1) | RS20050180A (fr) |
| SI (1) | SI1594858T1 (fr) |
| TW (1) | TW200407131A (fr) |
| UY (1) | UY27952A1 (fr) |
| WO (1) | WO2004020431A2 (fr) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1641780B1 (fr) * | 2003-06-24 | 2008-11-12 | Pfizer Products Incorporated | Procedes pour la preparation de derives de 1- 2-(benzimidazole-1-yl)quinoline-8-yl piperidine-4-ylamine |
| WO2005094830A1 (fr) * | 2004-03-30 | 2005-10-13 | Pfizer Products Inc. | Combinaisons d'inhibiteurs de transduction de signaux |
| GB0411421D0 (en) * | 2004-05-21 | 2004-06-23 | Glaxo Group Ltd | Novel compounds |
| WO2006038111A1 (fr) * | 2004-10-07 | 2006-04-13 | Pfizer Products Inc. | Derives de benzoimidazole utiles en tant qu'agents antiproliferatifs |
| CA2763671A1 (fr) | 2005-04-26 | 2006-11-02 | Pfizer Inc. | Anticorps de la p-cadherine |
| NZ566774A (en) | 2005-09-07 | 2011-11-25 | Pfizer | Human monoclonal antibodies to activin receptor-like kinase-1 |
| EP2258700A1 (fr) | 2006-05-09 | 2010-12-08 | Pfizer Products Inc. | Dérivés d'acides aminés cycloalkyles et compositions pharmaceutiques les contenant |
| NZ580327A (en) | 2007-04-03 | 2012-02-24 | Array Biopharma Inc | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS |
| TWI472529B (zh) * | 2008-05-21 | 2015-02-11 | Incyte Corp | ２－氟－Ｎ－甲基－４－〔７－（喹啉－６－基－甲基）－咪唑并〔１，２－ｂ〕〔１，２，４〕三－２－基〕苯甲醯胺之鹽類及其相關製備方法 |
| US10420665B2 (en) | 2010-06-13 | 2019-09-24 | W. L. Gore & Associates, Inc. | Intragastric device for treating obesity |
| US9526648B2 (en) | 2010-06-13 | 2016-12-27 | Synerz Medical, Inc. | Intragastric device for treating obesity |
| US8628554B2 (en) | 2010-06-13 | 2014-01-14 | Virender K. Sharma | Intragastric device for treating obesity |
| US10010439B2 (en) | 2010-06-13 | 2018-07-03 | Synerz Medical, Inc. | Intragastric device for treating obesity |
| JP6039559B2 (ja) | 2010-09-02 | 2016-12-07 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | Ｌｐａ受容体アンタゴニストとしてのピラゾロピリジノン誘導体 |
| GB201103578D0 (en) | 2011-03-02 | 2011-04-13 | Sabrepharm Ltd | Dipyridinium derivatives |
| KR101738063B1 (ko) | 2012-09-21 | 2017-05-19 | 아로그 파마슈티칼스, 인코퍼레이티드 | 구조적으로 활성인 인산화된 ｆｌｔ３ 키나제의 억제 방법 |
| TWI599356B (zh) | 2012-09-26 | 2017-09-21 | 安羅格製藥有限責任公司 | 抑制突變型ｃ－ｋｉｔ的方法 |
| US10835525B2 (en) | 2012-09-26 | 2020-11-17 | Arog Pharmaceuticals, Inc. | Method of inhibiting mutant C-KIT |
| US11642340B2 (en) | 2012-09-26 | 2023-05-09 | Arog Pharmaceuticals, Inc. | Method of inhibiting mutant C-KIT |
| BR112015016282A2 (en) | 2013-01-07 | 2017-07-11 | Arog Pharmaceuticals, Inc. | crenolanib for treatment of mutated flt3 proliferative disorders |
| US10463658B2 (en) | 2013-10-25 | 2019-11-05 | Videra Pharmaceuticals, Llc | Method of inhibiting FLT3 kinase |
| TR201900148T4 (tr) * | 2014-10-31 | 2019-02-21 | Genoscience Pharma Sas | Kansere karşı yeni maddeler olarak sübstitüe edilmiş 2,4 diamino-kinolin. |
| GB2543550A (en) | 2015-10-21 | 2017-04-26 | Hox Therapeutics Ltd | Peptides |
| US10779980B2 (en) | 2016-04-27 | 2020-09-22 | Synerz Medical, Inc. | Intragastric device for treating obesity |
| DK3452465T3 (da) * | 2016-05-04 | 2021-02-08 | Genoscience Pharma | Substituerede 2,4-diaminoquinolinderivater til anvendelse til behandling af proliferative sygdomme |
| US12534764B2 (en) | 2016-11-02 | 2026-01-27 | Arog Pharmaceuticals, Inc. | Crenolanib for treating FLT3 mutated proliferative disorders associated mutations |
| EA201991078A1 (ru) | 2016-11-02 | 2019-11-29 | Креноланиб для лечения пролиферативных расстройств, связанных с мутацией flt3 | |
| CN107382984B (zh) * | 2017-08-24 | 2020-07-10 | 扬州市三药制药有限公司 | 一种治疗白血病药物的制备方法 |
| CN107382983B (zh) * | 2017-08-24 | 2020-08-07 | 扬州市三药制药有限公司 | 一种治疗白血病药物的合成方法 |
| CN110840893A (zh) | 2018-12-13 | 2020-02-28 | 安罗格制药有限责任公司 | 含克莱拉尼的药物组合物及其用途 |
| US11471451B2 (en) | 2019-08-19 | 2022-10-18 | Arog Pharmaceuticals, Inc. | Uses of crenolanib |
| CN117447376A (zh) * | 2019-12-09 | 2024-01-26 | 苏州恩华生物医药科技有限公司 | 连双环结构sigma-1受体抑制剂 |
| CN118767143A (zh) | 2019-12-12 | 2024-10-15 | 听治疗有限责任公司 | 用于预防和治疗听力损失的组合物和方法 |
| CA3186319A1 (fr) * | 2020-07-20 | 2022-01-27 | Arog Pharmaceuticals, Inc. | Formes cristallines de crenolanib et leurs procedes d'utilisation |
| WO2022019998A1 (fr) | 2020-07-20 | 2022-01-27 | Arog Pharmaceuticals, Inc. | Formes cristallines de crénolanib et leurs procédés d'utilisation |
| CN116234549B (zh) * | 2020-08-05 | 2025-11-25 | 总医院公司 | 盐诱导激酶抑制剂 |
| US11524006B2 (en) | 2020-09-17 | 2022-12-13 | Arog Pharmaceuticals, Inc. | Crenolanib for treating TRK kinase associated proliferative disorders |
| US11969420B2 (en) | 2020-10-30 | 2024-04-30 | Arog Pharmaceuticals, Inc. | Combination therapy of crenolanib and apoptosis pathway agents for the treatment of proliferative disorders |
| WO2022090547A1 (fr) | 2020-10-30 | 2022-05-05 | Dsm Ip Assets B.V. | Production de caroténoïdes par fermentation |
| CN113683594B (zh) * | 2021-09-07 | 2022-12-27 | 曲靖师范学院 | 一种喹啉-苯并咪唑盐类化合物及其合成方法和应用 |
| JP2023063189A (ja) | 2021-10-22 | 2023-05-09 | アログ・ファーマシューティカルズ・インコーポレイテッド | 以前の治療に対して再発性／不応性のｆｌｔ３突然変異増殖性障害を治療するためのクレノラニブ |
| AU2022379973A1 (en) | 2021-11-08 | 2024-06-27 | Progentos Therapeutics, Inc. | Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof |
| CN114409632B (zh) * | 2022-02-22 | 2024-04-30 | 北京鲲达宇科技有限公司 | 2-取代氨基-3-苯并咪唑取代的喹啉衍生物及其制备方法与应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8607683D0 (en) | 1986-03-27 | 1986-04-30 | Ici Plc | Anti-tumor agents |
| US5990146A (en) | 1997-08-20 | 1999-11-23 | Warner-Lambert Company | Benzimidazoles for inhibiting protein tyrosine kinase mediated cellular proliferation |
| AU744939B2 (en) | 1997-09-26 | 2002-03-07 | Merck & Co., Inc. | Novel angiogenesis inhibitors |
| UA75055C2 (uk) * | 1999-11-30 | 2006-03-15 | Пфайзер Продактс Інк. | Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі |
| AU784589B2 (en) * | 1999-11-30 | 2006-05-04 | Board Of Trustees Of The Leland Stanford Junior University | Bryostatin analogues, synthetic methods and uses |
| JP2008002005A (ja) * | 2006-06-21 | 2008-01-10 | Shimada Shoji Kk | 衣服用パッド |
-
2003
- 2003-08-12 PA PA8580301A patent/PA8580301A1/es unknown
- 2003-08-14 GE GEAU2003008665 patent/GEP20064005B/en unknown
- 2003-08-14 HR HRP20050191AA patent/HRP20050191B1/hr not_active IP Right Cessation
- 2003-08-14 EA EA200500174A patent/EA008448B1/ru not_active IP Right Cessation
- 2003-08-14 OA OA1200500059A patent/OA12916A/en unknown
- 2003-08-14 PL PL37767803A patent/PL377678A1/pl not_active Application Discontinuation
- 2003-08-14 AU AU2003250499A patent/AU2003250499B2/en not_active Ceased
- 2003-08-14 SI SI200331687T patent/SI1594858T1/sl unknown
- 2003-08-14 KR KR20057003493A patent/KR100816166B1/ko not_active Expired - Fee Related
- 2003-08-14 CA CA 2495577 patent/CA2495577C/fr not_active Expired - Lifetime
- 2003-08-14 CN CNB038206218A patent/CN1319966C/zh not_active Expired - Lifetime
- 2003-08-14 ES ES03791110T patent/ES2333219T3/es not_active Expired - Lifetime
- 2003-08-14 PT PT03791110T patent/PT1594858E/pt unknown
- 2003-08-14 AT AT03791110T patent/ATE445610T1/de active
- 2003-08-14 KR KR1020077014809A patent/KR20070086768A/ko not_active Ceased
- 2003-08-14 JP JP2004569727A patent/JP4551771B2/ja not_active Expired - Lifetime
- 2003-08-14 NZ NZ538427A patent/NZ538427A/en not_active IP Right Cessation
- 2003-08-14 EP EP20030791110 patent/EP1594858B1/fr not_active Expired - Lifetime
- 2003-08-14 BR BRPI0313942A patent/BRPI0313942C1/pt not_active IP Right Cessation
- 2003-08-14 DK DK03791110T patent/DK1594858T3/da active
- 2003-08-14 WO PCT/IB2003/003634 patent/WO2004020431A2/fr not_active Ceased
- 2003-08-14 MX MXPA05001256A patent/MXPA05001256A/es active IP Right Grant
- 2003-08-14 AP AP2005003237A patent/AP2005003237A0/xx unknown
- 2003-08-14 DE DE60329715T patent/DE60329715D1/de not_active Expired - Lifetime
- 2003-08-19 DO DO2003000694A patent/DOP2003000694A/es unknown
- 2003-08-25 HN HN2003000257A patent/HN2003000257A/es unknown
- 2003-08-25 PE PE2003000864A patent/PE20050131A1/es active IP Right Grant
- 2003-08-26 MY MYPI20033225 patent/MY139357A/en unknown
- 2003-08-26 US US10/648,151 patent/US7071337B2/en not_active Expired - Lifetime
- 2003-08-26 AR ARP030103073 patent/AR041055A1/es unknown
- 2003-08-26 UY UY27952A patent/UY27952A1/es not_active Application Discontinuation
- 2003-08-27 TW TW92123585A patent/TW200407131A/zh unknown
-
2005
- 2005-01-20 IS IS7660A patent/IS2738B/is unknown
- 2005-02-10 IL IL166832A patent/IL166832A/en active IP Right Grant
- 2005-02-14 CU CU20050031A patent/CU23413B7/es not_active IP Right Cessation
- 2005-02-22 CR CR7698A patent/CR7698A/es unknown
- 2005-02-28 MA MA28124A patent/MA27389A1/fr unknown
- 2005-02-28 EC ECSP055633 patent/ECSP055633A/es unknown
- 2005-03-14 NO NO20051303A patent/NO20051303L/no not_active Application Discontinuation
- 2005-08-14 RS YUP-2005/0180A patent/RS20050180A/sr unknown
-
2009
- 2009-11-30 CY CY20091101249T patent/CY1110580T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA27389A1 (fr) | Derives de benzimidazole nouveaux utiles comme agents antiproliferatifs. | |
| MA28747B1 (fr) | Dérivés de pyridine | |
| EP1328269B2 (fr) | Association d'un antagoniste du recepteur cb1 et de la sibutramine pour le traitement de l'obesite | |
| MA29926B1 (fr) | Derives de pyrazine | |
| MA67365B1 (fr) | Dérivés de benzisoxazole sulfonamide | |
| CA2153340C (fr) | Application du riluzole dans le traitement de la maladie de parkinson et des syndromes parkinsoniens | |
| MA27568A1 (fr) | Derives de pyrrolopyrimidine | |
| MA28064A1 (fr) | Dérivés de pyrrolo [3,4-c] pyrazole actifs comme inhibiteurs de kinases | |
| TN2009000428A1 (fr) | Derives de sulfonylamides destines au traitement d'une croissance cellulaire anormale | |
| MA31466B1 (fr) | Derives de benzimidazole | |
| MA30075B1 (fr) | Derives de pyrimidine pour le traitement d'une croissance cellulaire anormale | |
| MA32009B1 (fr) | Nouveaux derives de pyrazolo [3,4-d]pyrimidine en tant qu'agents anticancereux | |
| MA27009A1 (fr) | Derives de pyrazole pour le traitement d'une infection par le vih | |
| TNSN04156A1 (fr) | Pyridinones substituees servant de modulateurs de la map-kinase p38 | |
| TNSN05250A1 (fr) | Pyrimidinones substituees | |
| MA29791B1 (fr) | Composes therapeutiques. | |
| MA27990A1 (fr) | Derives de piperazine pour le traitement d'infections par le vih | |
| TNSN04246A1 (fr) | Derives d'heteroarylamides benzocondenses de thienopyridines utiles comme agents therapeutiques, compositions pharmaceutiques les contenant et methodes pour leur utilisation | |
| MA27867A1 (fr) | Nouveaux derives de 2h-pyridazine-3-one, compositions pharmaceutiques contenant ces derives et procede de preparation de l'ingredient actif. | |
| MY130668A (en) | Isothiazole derivatives useful as anticancer agents | |
| MA27095A1 (fr) | Formes de sels de e-2 -methoxy-n-(3-(4-(3-methyl-pyridine-3-yloxy)-phenylamino)-quinazoline-6-yl)-allyl)-acetamide, leur preparation et leur utilisation contre le cancer | |
| MA26960A1 (fr) | Sels d'un isothiazole-4-carboxamide et leur utilisation comme agent anti-hyperproliferation | |
| MA27560A1 (fr) | Nouveaux derives de fluorglycoside heterocycliques, produits pharmaceutiques contenant ces composes et leur utilisation | |
| TN2009000450A1 (fr) | Derives de pyridine | |
| MA27142A1 (fr) | Derives de piperazine a activite antagoniste des recepteurs ccr1 |